A true story of how a biopharmaceutical company in North Wales transformed its fortunes in five years to secure its future with employee surveys.
2004: Ipsen Biopharm ceases manufacture of their core product and makes around 100 people redundant, a third of the workforce. The future success of the company relies on launching its up and coming product in the US market, but that requires license approval by the FDA (US Food & Drugs Agency), by no means a foregone conclusion. The very future of the site is on the line. Morale is low, working practices are outdated, and there is little trust and cooperation between management and staff.
Absenteeism is running at 8-9%